project id: TCGA-PRAD; case submitter id: TCGA-ZG-A9L9; source center: 23; state: released; a260 a280 ratio: 1.83; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.24; rna integrity number: 7.4; age at index: 60; days to birth: -22108; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1952; age at diagnosis: 22108; ajcc clinical m: M0; ajcc clinical t: T2b; ajcc pathologic n: N1; ajcc pathologic t: T3b; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 617.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 4; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 5; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2012; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 665; initial weight: 270.0; sample id: 6dd21ac6-0657-4bf3-a3ef-b8b5ba0da625; sample submitter id: TCGA-ZG-A9L9-01A; portion id: 0a240f39-fa84-44c4-aed1-3388d0cd719f; portion submitter id: TCGA-ZG-A9L9-01A-11; slide id: 2dd3c7a9-8b07-4a8a-a3ea-9a95d537833e; slide submitter id: TCGA-ZG-A9L9-01A-01-TSA; percent lymphocyte infiltration: 2.0; percent monocyte infiltration: 1.0; percent necrosis: 0.0; percent neutrophil infiltration: 1.0; percent normal cells: 3.0; percent stromal cells: 22.0; percent tumor cells: 75.0; percent tumor nuclei: 75.0; section location: TOP;